For women, semaglutide can come with unique challenges, like more frequent gastrointestinal symptoms and changes in menstrual cycles
The most frequent gastrointestinal side effects include: Nausea and vomiting : Very common, typically most pronounced during dose escalation Diarrhoea : Common to very common, though usually mild to moderate Constipation : Can occur due to delayed gastric emptying and reduced gut motility Abdominal pain and discomfort : Common Dyspepsia and gastro-oesophageal reflux : May worsen in susceptible individuals Other important adverse effects include: Gallbladder disorders : Cholelithiasis and cholecystitis have been reported, particularly with weight loss Dehydration and acute kidney injury : May occur secondary to severe gastrointestinal symptoms Hypoglycaemia : Risk increases when used with insulin or sulfonylureas, which may require dose adjustment Current limited evidence does not suggest an increased risk of inflammatory bowel disease (IBD) flares with GLP-1 agonists, though more data are needed
Although no clinically relevant interactions have been consistently observed in clinical trials, caution is advised, especially with drugs that require rapid gastrointestinal absorption or have a narrow therapeutic index
Food and Drug Administration (FDA) Sentinel and EudraVigilance serve as national and international data warehouses that support expending surveillance of rare oncologic adverse events associated with neoplasms of oncologic proportions
Prioritize these crucial factors: Physician Credentials: Ensure the clinic employs board-certified physicians with extensive experience in weight management and semaglutide administration
